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Abstract: Dr. Young-Ki Paik directs the Yonsei Proteome Research Center in Seoul, Korea 
and was elected as the President of the Human Proteome Organization (HUPO) in 2009. In 
the December 2009 issue of the Current Pharmacogenomics and Personalized Medicine 
(CPPM), Dr. Paik explains the new field of pharmacoproteomics and the approaching wave 
of “proteomics diagnostics” in relation to personalized medicine, HUPO‟s role in advancing 
proteomics technology applications, the HUPO Proteomics Standards Initiative, and the 
future impact of proteomics on medicine, science, and society. Additionally, he comments 
that (1) there is a need for launching a Gene-Centric Human Proteome Project (GCHPP) 
through which all representative proteins encoded by the genes can be identified and 
quantified in a specific cell and tissue and, (2) that the innovation frameworks within the 
diagnostics industry hitherto borrowed from the genetics age may require reevaluation in the 
case of proteomics, in order to facilitate the uptake of pharmacoproteomics innovations. He 
stresses the importance of biological/clinical plausibility driving the evolution of 
biotechnologies such as proteomics, instead of an isolated singular focus on the technology 
per se. Dr. Paik earned his Ph.D. in biochemistry from the University of Missouri-Columbia 
and carried out postdoctoral work at the Gladstone Foundation Laboratories of 
Cardiovascular Disease, University of California at San Francisco. In 2005, his research team 
at Yonsei University first identified and characterized the chemical structure of C. elegans 
dauer pheromone (daumone) which controls the aging process of this nematode. He is 
interviewed by a multidisciplinary team specializing in knowledge translation, technology 
regulation, health systems governance, and innovation analysis. 
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INTERVIEW 
1. The Science of Proteomics 
CPPM: Thank you for agreeing to this interview, Dr. Paik. Our readership and certainly the 
general public are probably far more familiar with the language and science of genomics. 
We‟re wondering if you can give us a working definition of “proteomics” and 
“pharmacoproteomics” and perhaps provide some examples? 
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Paik: A broad working definition of proteomics may be that proteomics is a high-throughput, 
data-rich, comprehensive, systematic, large-scale, and quantitative analysis of the expression 
of proteins and their associated peptides in biological/clinical samples obtained under specific 
(patho) physiological settings. Thus, proteomics provides a unique means to gain insights into 
the relative abundance of protein components present in complex biological samples, a 
capability that is important for the discovery of biomarkers and novel drug targets. 
Pharmacoproteomics, a term that is a synthesis of “pharmacology” and “proteomics”, refers 
to the comprehensive proteomics analysis that is relevant to novel drug target discovery, drug 
metabolism, as well as drug efficacy and toxicity. A systematic qualitative and quantitative 
monitoring of proteomics changes before and after drug treatment can be seen in many 
recently published papers. For example, Singh et al. [1] examined the protein expression 
using two-dimensional electrophoresis (2DE) in IB3-1 cystic fibrosis bronchial epithelial 
cells and identified proteins that were differentially expressed in response to treatment of 
these cells with 4-phenylbutyrate, a drug used to treat the urea cycle disorders. The 
pharmacoproteomics profiling of drug treatment provides a deeper understanding of potential 
side effects [2, 3], mechanism of action [4], and proteindrug/protein-protein interactions [5] 
by measuring the dynamic and functional changes in genes or proteins involved in drug 
metabolism and molecular drug targets.  
 
CPPM: With the approaching wave of pharmacoproteomics, systems biology and other more 
“dynamic” measures of cellular physiology in health and disease, complexities and 
opportunities in postgenomics medicine are rapidly growing. Looking through and beyond 
the context of personalized drug therapy, what are the unique advantages and limitations of 
proteomics technology in comparison to genomics? Is pharmacoproteomics fundamentally 
similar or different than pharmacogenomics? It is often stated that genomics technologies 
offer a higher throughput at the cost of a functional read out of cellular (patho)physiology at 
the proteome level, whereas proteomics offers a more integrated impact of genomic variation 
on protein function, but at a relatively slower throughput than genomics technology 
platforms. How can a better understanding of genomics and proteomics approaches in tandem 
help overcome the artificial compartmentalization of omics technologies on the critical path 
to personalized medicine? 
Paik: Proteomics deals with protein expression in complex clinical specimens, yielding 
quantitative, functional and structural profiling, e.g., of post-translational modifications 
(PTM), of specific proteins of interest for a diverse array of phenotypes concerning disease 
susceptibility, normal physiology and health intervention outcomes. In contrast, 
pharmacogenomics primarily deals with variability in further upstream elements in the 
biological cascade, e.g., genetic sequence and transcriptome diversity as opposed to 
integrated downstream variations in the proteome. Both pharmacogenomics and 
pharmacoproteomics have nonetheless been very useful for predicting the efficacy and 
toxicity of drug therapy and when applicable, tailoring drug therapy, with the goal of 
reducing side effects and enhancing efficacy. Given the close relationship between 
personalized medicine and biomarker development, genome-wide profiling may complement 
pharmacoproteomics studies. Thus, these two fields are more complementary than they are 
competitive or mutually exclusive. Indeed, without genomic sequence information, 
proteomics would face a tremendous barrier in the identification of proteins and their variants 
involved in disease. Thus, based on this consensus, when we say “unique advantage” of 
proteomics in regard to diagnosis or treatment, perhaps the proteomics approach allows us to 
analyse alterations in posttranslational modification of a specific biomarker that reflects the 
functional signature of human diseases at different stages before and after their clinical 
manifestations are apparent and measurable. Genomics, in particular sequencebased 
genomics technologies, do not have this capability and cannot be used to design such 
dynamic disease biomarkers (e.g., the fucosylated fraction of alpha-fetoprotein, L3, is used as 
a useful prognostic marker in patients with hepatocellular carcinoma). The application of 
clinical proteomics through the use of, for example, a panel of blood biomarkers for 
diagnostic or prognostic tests will contribute towards a rational basis for future personalized 
medicine. Of course, like other „omics‟ disciplines, proteomics has some limitations. It is 
noteworthy that no technical tool exists to observe protein expression in real time, in contrast 
to what is now routinely practiced for the analysis of gene expression through real time qRT-
PCR. In addition, proteomics heavily depends on very expensive equipment (e.g., high-
resolution mass spectrometer) and associated bioinformatics tools (e.g., search engines) to 
identify the correct proteins of interest. It is to be noted, however, that the throughput of 
proteomics technologies have increased appreciably with the recent introduction of protein 
arrays. A number of nuanced distinctions between pharmacoproteomics and its counterpart, 
pharmacogenomics deserve further emphasis. These include differences with respect to target 
molecules (protein or peptides vs. gene or mRNA), assay profile (protein 
modification/quantification vs. gene polymorphism/expression), and interaction pattern 
(direct protein-drug/protein-protein vs. predicted gene interaction/expression 
network/epistasis). Hancock‟s group [6] recently used “shot-gun proteomics” to analyse 
changes in protein expression in a non-small cell lung cancer cell line (EKVX cell lines) 
during the course of drug treatment. Their results indicate that the synergistic cytotoxicity of 
drugs used for cancer cell suppression can be further used for evaluation of drug therapy in 
cancer. In addition, multiple reaction monitoring (MRM) techniques employed in proteomics 
may eventually allow us to move from discovery to routine assay in clinical proteomics of 
cancer research. Finally, with MRM and other associated techniques, one can directly 
identify disease-causing protein alterations, such as protein truncation, structural 
modification, and changes in protein expression. Importantly, coordinated use of genomics 
and proteomics in tandem can offer mechanistic triangulation of biomarker data, and 
discovery and validation of diagnostic tests on the critical path to personalized health 
interventions, whether they concern drug treatment, nutrition or vaccines. 
 
CPPM: Historically, proteomics technology dates back to the late 1970s, so it‟s actually 
older than genomics or high-throughput genome sequencing which developed much later as 
part of the Human Genome Project in 1990s [7-9]. What do you think are the reasons for the 
apparent delay in introduction of proteomics diagnostics compared to genomics tests in 
personalized medicine? Are there certain medical specialties and therapeutic areas where 
pharmacoproteomics offers substantial promise? 
Paik: You are correct that proteomics technology is much older than many people are 
presently aware. However, 2DE and LC-based separation have been the most common tools 
used in proteomics, and the absence of mass spectrometry (MS) for high throughput 
identification of proteins/peptides has delayed the development of the field into its current 
state. In other words, the overall speed of proteomics utilization has been dependent on the 
development of MS. Therefore, the delay in application of proteomics to the diagnostics field 
can be mostly attributed to the pace of development and application of MS to the analysis of 
proteins and peptides. For example, methods for detection of proteins (not small molecules) 
by MS were only introduced between the late 80s and early 90s. Furthermore, the application 
of proteomics to the diagnostics field with regard to personalized medicine was 
conceptualized early this (21st) century under the theme of biomarker discovery and 
validation. As mentioned earlier, proteomics heavily relies on the genomics information (e.g., 
the human genome sequence). This information became publicly available only in 2003. In 
the meantime, genomics tools and molecular biology techniques have progressed without 
much restriction. This has allowed scientists to mobilize all these techniques (e.g., RFLP, 
DNA microarrays, and SNP detection) to identify mutations and polymorphisms in samples 
obtained from disease tissue. One restriction that proteomics has faced is clinical specimen 
complexity, which may have contributed to the delay in the direct application of proteomics 
to clinical diagnosis such as biomarker discovery and predictive testing [10, 11]. For 
example, the strategy of depletion of high-abundance proteins from blood specimens became 
available only 5 to 6 years ago [12]. There are many factors to consider with regard to the 
potential promise of pharmacoproteomics in the clinical sector. For example, as opposed to 
genomics techniques, pharmacoproteomics shall shed light on the drug action mechanism, the 
elucidation of which requires detailed information on the structure and function of drug-
metabolizing proteins as well as molecular drug targets. With pharmacoproteomics tools, one 
can view every single reaction elicited by a drug inside a cell and identify the major protein 
players during drug action. For example, Butler and colleagues [13] used 
pharmacoproteomics techniques to track down dynamic patterns in cell membrane changes, 
and gained other molecular insights following metalloproteinase inhibitor treatment. Because 
the feasibility of proteomics analyses ultimately depends on tissue access, medical specialties 
where this is readily feasible might conceivably be the “lowest hanging fruits” during the 
implementation phase of clinical pharmacoproteomics (e.g., oncology, infectious diseases, 
haematological disorders and possibly, dermatology).  
 
2. The Role of the Human Proteome Organization 
CPPM: You started a two-year term as the Human Proteome Organization (HUPO) President 
in January 2009. What role does HUPO play in advancing proteomics science? Do 
pharmacoproteomics and personalized medicine already represent some of the key focus 
areas for HUPO? 
Paik: This is a quite interesting question for everyone involved in HUPO. First of all, I must 
give full credit to my predecessors, Drs. Sam Hanash, John Bergeron, and Rolf Apweiler. All 
did pioneering work in organizing the HUPO initiatives, which have been a driving force in 
advancing many aspects of proteomics science. For example, in 2001, HUPO started several 
proteomics initiatives including the Plasma Proteome Project (chaired by Gil Omenn), 
Proteomics Standards Initiative (PSI, chaired by Rolf Apweiler), Brain Proteome Project 
(chaired by Helmut Meyer), Liver Proteome Project (HLPP, chaired by Fuchu He), Antibody 
Initiative (chaired by Mathias Uhlen), and Glycoproteomics (chaired by Naoyuki Taniguchi). 
These pivotal HUPO initiatives are designed to stimulate the foundation and development of 
various protein standards and techniques that are commonly used for proteomics studies. 
Collectively, HUPO provides international and transdisciplinary leadership and a standard for 
dataset generation as well as tools for sharing, depositing, and retrieving proteomics data 
[14]. In the years following the term of John Bergeron (2nd President) and Rolf Apweiler 
(3rd President), identification of disease biomarkers relevant to each HUPO initiative, e.g., 
the liver cancer biomarkers for the Human Proteome Project (HPP) and the Human Liver 
Proteome Project (HLPP) have continued to grow and presently emerged as some of the key 
themes of the HUPO projects. Needless to say, biomarkers have become one of the most 
important parts of personalized medicine as well as pharmacoproteomics. Biomarkers are 
increasingly becoming one of the major focuses of HUPO initiatives.  In terms of the 
technology, HUPO offers stewardship and facilitates scientific exchange and dissemination 
of the cutting edge techniques to improve the limits of detection, resolution, and 
identification of proteins present in the biological samples and mixtures. These techniques are 
wide ranging and include MS, chromatography, fractionation, sample preparation, and 
proteome informatics. The annual HUPO congress usually provides a common meeting place 
for all stakeholders involved in proteomics and illustrates the advancements in analytical 
tools and technologies and their applications in postgenomics biology and medicine. 
Although pharmacoproteomics and personalized medicine are directly represented at the 
HUPO, these important themes have been, and will continue to be addressed within the 
context of clinical proteomics at the annual congresses. 
 
CPPM: Could you tell us about the HUPO Proteomics Standards Initiative (PSI)? What are 
its key objectives, who is involved, and how is it structured? 
Paik: The PSI defines the community standards for data representation in proteomics to 
facilitate data comparison, exchange, and verification [15, 16]. PSI is organized in several 
working groups such as Protein Separation, Mass Spectrometry, Molecular Interactions, 
Protein Modifications, and Proteomics Informatics. All working groups address issues of data 
transport (through the collaborative development of XML schemata), description by 
controlled vocabularies to agreed levels of detail, and deposition in databases. PSI strongly 
supports and encourages data sharing between such repositories. Henning Hermjakob (UK), 
Randall Julian (USA) and Eric Deutsch (USA) serve as the current chairpersons of the PSI. 
They would be an excellent resource for various stakeholders and the CPPM readership with 
an interest in the HUPO PSI. More details on current activities and accomplishments of 
HUPO PSI are available on the web as well [16]. Needless to say, such efforts to develop 
proteomics standards are an essential prerequisite before proteomics diagnostics can come to 
fruition in personalized medicine as well as for future discovery and translational research in 
postgenomics medicine. 
 
3. Proteomics, Medicine, and Society 
CPPM: In the specific context of personalized medicine and therapeutics, what are some 
realistic schemas under which human proteome variation and the emerging technologies 
might be effectively integrated with social determinants of health and clinical practice, and 
further reconciled with environmental and ethical issues? In a broader context, what are your 
thoughts on the emerging practice of 21st century diagnostic medicine? 
Paik: First of all, in my personal opinion, human proteome variation [17], which is caused by 
modification of mature proteins at the cellular level and is not coded in detail by genomic 
information, must be distinguished from human genome variation, which causes alterations in 
the primary sequence of yet to be processed immature proteins. Of course, variation in both 
the genome and proteome is directly or indirectly involved in disease. Genome variation can 
easily be detected by PCR or routine molecular biological techniques, but proteome variation 
can only be detected by MS or other chemical methods following exhaustive separation. 
Thus, a more realistic schema under which human proteome variation relevant to disease 
could become a part of routine clinical practice would be a so-called integrated analytical 
system for proteome variation (IASP), which is based on the MS-based proteomics tool. The 
IASP may include MRM or SRM (single reaction monitoring) for identification and 
quantification of post-translationally modified peptides that are directly related to certain 
diseases. The IASP will be very compatible with social consensus and ethical issues because 
it is similar to existing diagnostic procedures in medicine. However, for IASP to be integrated 
into routine clinical practice, we need to carry out additional work on advanced MS detection, 
quantification standards, and general standardization of clinical sample collection and ways 
in which such procedures will be acceptable to different stakeholders such as physicians, 
scientists, diagnostic industry, regulators and policy-makers. It is also essential to consider 
population health in different countries and how best to utilize proteomics in the latter 
context, so that the existing gaps in biotechnology between developed and developing 
countries are remedied or at the very least, not widened further. From a comprehensive and 
long-term perspective, there is a strong need for launching a Gene-Centric Human Proteome 
Project (GC-HPP) through which all representative proteins (ORF) encoded by genes can be 
identified and quantified in a specific cell and tissue. This GC-HPP shall provide a basic 
parts list [18] of the human proteome that can serve as a “textbook” of the protein variants 
present in a given cell under given disease conditions. To this end, it can be noted that the 
study of biological variations can be further contextualized by ever present interactions with 
the environment in which a host (e.g., a patient) resides. In this sense, then, proteomics can 
also be seen as an attempt to identify environmental (including social) factors that impact 
human proteome variation in concert. 
 
CPPM: Some communities are critical that personalized medicine applications will, in fact, 
not be a part of routine clinical medicine. They are concerned that inequities will occur with 
regards to access to such diagnostics, which can be expected to be expensive at first. Can you 
give us your thoughts? 
Paik: If I understand this question correctly, with regard to routine clinical medicine where 
proteomics techniques are being applied to (e.g., standard MRM for disease biomarker 
quantification in normal and disease samples), we can consider establishing local proteomics 
analysis service providers through which any local clinic can request a simple proteomic 
analysis of patients‟ sample. For some analyses such as specific disease biomarker panels, 
each clinic can analyse a patient‟s sample on a disease-specific protein chip and compare the 
resulting pattern of readings to patterns present in a standardized database. A so-called online 
service might conceivably be established through the network of personalized medicine. 
Proteomics analytical equipment such as highresolution mass spectrometers and related 
software are generally very expensive, but the consumables are not. Perhaps the clinical 
proteomics society can organize some type of consortium and share those facilities and 
databases for routine analyses. Still, regulation of proteomics diagnostics, their equitable 
development and availability in the clinic from various channels (e.g., direct to consumer 
versus at physician‟s office) are areas for further social and policy reflection. 
 
CPPM: Past experience with genetically modified organisms (GMOs), stem cell research, 
and other health technologies have taught us some lessons – that it is not just scientific 
concerns that are important to the uptake of innovative technologies. The public‟s perceptions 
of scientific, regulatory, legal, marketing, and health insurance frameworks are also 
important. Is HUPO prepared to address these sorts of issues, and if so, how? 
Paik: Although some of my colleagues in the clinical sectors might have already addressed 
these issues, it is my opinion that, at the organizational level, HUPO has not yet fully 
prepared for this issue. Maybe this could be the starting point for considering this issue 
seriously. 
 
4. Future Outlook 
CPPM: Could you briefly tell us your vision of the anticipated trajectory of proteomics, 
personalized medicine, and the attendant role of HUPO for the next ten years? For one thing, 
protein expression varies over time and context and hence, will likely shift the risk 
assessment models in personalized medicine from a static “one-time” evaluation of risks 
(e.g., genotype-dependent drug toxicity, lack of efficacy) to a more dynamic, ongoing and 
“repeated measures approach” to risk assessment. Business models, too, may likely change in 
the diagnostic industry to accommodate such technical nuances that can in turn have hard 
impacts on the development and uptake of proteomics innovations in personalized medicine. 
Any thoughts in these aspects of pharmacoproteomics and proteomics diagnostics more 
generally? 
Paik: In my view, it is very clear that proteomics and pharmacoproteomics, along with 
genomics/pharmacogenomics, will be integral components of personalized medicine in the 
continuum from discovery, translation and clinical implementation. In the context of HUPO‟s 
role in personalized medicine, HUPO may provide the community with standard samples for 
protein identification and quantification, Standard Operating Procedures (SOPs), education, 
training, and other related public services that can be effectively applied to personalized 
medicine. HUPO has a long standing and credible track record filling such a role, as already 
seen in the case of our major initiatives (e.g., HPPP, PSI, and others). A good partnership 
must exist between all interested groups (e.g., clinicians, proteomics scientists, and 
bioinformaticians) to boost the realization of proteomics as one of the engines running 
personalized medicine. This partnership can be promoted by HUPO, which can create a 
transdisciplinary forum to facilitate the confluence of personalized medicine, 
pharmacoproteomics and pharmacogenomics. Business and innovation frameworks from the 
genomics age may need reevaluation when applied to proteomics-based diagnostics, since 
proteomics tests may need to be ordered more than once at different times or contexts by the 
clinicians. In this regard, evidence based criteria based on biological or clinical plausibility 
should drive the evolution of biotechnologies such as proteomics, rather than a sole isolated 
focus on the technology per se. Ultimately, proteomics may offer a much needed perspective 
to evaluate the plasticity of human physiology in health and disease, i.e., time or context 
dependent changes in protein expression and attendant impacts on the function of the cell and 
whole organisms and ecosystems. 
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ABBREVIATIONS 
2DE = Two-dimensional electrophoresis 
GC-HPP = Gene-Centric Human Proteome Project 
HUPO = Human Proteome Organization 
HLPP = Human Liver Proteome Project 
IASP = Integrated analytical system for proteome variation 
MRM = Multiple reaction monitoring 
MS = Mass Spectrometry 
PSI = HUPO Proteomics Standards Initiative 
PTM = Post-translational modifications 
SRM = Single reaction monitoring 
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